Search Results < Yale Cancer Center

174 results

News
Dr Chiang on Frontline Treatment Combinations in ES-SCLC
Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.
Source: OncLive
25 May 2023
News
Blavatnik Fund for Innovation at Yale Awards $2.5 Million to 11 Faculty-Led Projects
The Blavatnik Fund for Innovation at Yale, made possible by a generous grant from the Blavatnik Family Foundation, supports Yale faculty in the commercialization of biomedical and digital health innovations.
Source: Yale Ventures
24 May 2023
News
Dr Goldberg on Investigational Agents in EGFR-mutant NSCLC
Sarah Goldberg, MD, MPH, associate professor, internal medicine (medical oncology), associate director, Medical Oncology-Hematology Program, research director, Center for Thoracic Cancers, chief, Thoracic Oncology, Yale School of Medicine, discusses ongoing investigations with antibody-drug conjugates (ADCs) and bispecific antibodies in patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations.
Source: OncLive
24 May 2023
News
Yale Cancer Center and Smilow Cancer Hospital Physicians and Scientists Presenting Latest Advances at 2023 ASCO Annual Meeting
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.
18 May 2023
News
Pancreatic Cancer Vaccine Shows Promise, But When Will It Be Ready?
A new vaccine that uses mRNA technology and that can be customized for patients with pancreatic cancer has shown promising results in a small new study.
Source: Very Well Health
17 May 2023
News
Women’s Health Research at Yale Funds Studies to Improve Early Detection of Ovarian Cancer, Treatment of Prenatal Infections, and Aortic Aneurysm Outcomes in Women
Women's Health Research at Yale announces recipients of 2023 Pilot Project Program Grants
16 May 2023
News
CT researchers: Vaccine to fight cancer shows promise using same mRNA technology as COVID drug
The same technology that was used to create Moderna’s COVID-19 vaccine is being targeted on melanoma, and the treatment is having positive effects, according to researchers at the Yale Cancer Center. It’s another step in using the body’s immune system to fight diseases, using a person’s own mRNA to target cancer. The randomized Phase 2 study compares personalized mRNA vaccines given along with Keytruda, an immunotherapy drug with the generic name pembrolizumab, vs. giving Keytruda alone.
Source: The Hartford Courant
16 May 2023
News
Smilow Shares: Brain Tumor Awareness Month
On May 10, 2023, in honor of Brain Tumor Awareness Month, members of our Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center shared information on what to expect after surgery to remove a tumor.
11 May 2023
News
AEGEAN Trial Shows Benefit With Immunotherapy-Based Combination for NSCLC
Patients with treatment-naive resectable non–small cell lung cancer (NSCLC) treated with neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival and pathologic complete response rates compared with those who received neoadjuvant chemotherapy alone, according to an interim analysis of event-free survival and a final analysis of pathologic complete response in the phase III AEGEAN trial reported at the American Association for Cancer Research (AACR) 2023 Annual Meeting.
Source: ASCO Post
10 May 2023
News
The Caris Precision Oncology Alliance Welcomes Yale Cancer Center
Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Yale Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).
Source: Caris Life Sciences
9 May 2023
News
Get to Know … Amer Zeidan, MBBS, MHS
Dr. Zeidan, Associate Professor of Medicine at Yale University, Director of Early Therapeutics Research in Hematology and Assistant Medical Director of the Clinical Trials Office at Yale Cancer Center, and leader of Myeloid Malignancies and Leukemias DART (Disease Aligned Research Team) at Yale Comprehensive Cancer Center discusses a patient who shaped his career path, what he sees as the most pressing questions in the field, and more.
Source: Blood Cancers Today
8 May 2023
News
Maria Menounos reveals she beat pancreatic cancer after early detection: 'So lucky'
Maria Menounos has revealed that she beat pancreatic cancer after an early diagnosis in January. And now, she's advocating for others to be proactive about their health.
Source: USA Today
3 May 2023
News
New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues. The study was published in The Lancet on April 19, 2023.
2 May 2023
News
Dr. Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer
Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma (HNSCC) and lung cancer.
Source: OncLive
2 May 2023
News
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
Each year, Connecticut Magazine recognizes some of the state’s best physicians, who provide exceptional care for patients, with its annual “Top Doctors” issue. This year’s list includes 82 physicians from Smilow Cancer Hospital and Yale Cancer Center, the only National Cancer Institute-designated comprehensive cancer center in the state.
1 May 2023
News
Trastuzumab Deruxtecan vs Physician’s Choice in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine
As reported in The Lancet by André et al, the phase III DESTINY-Breast02 trial has shown improved progression-free survival with fam-trastuzumab deruxtecan-nxki vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received prior ado-trastuzumab emtansine. Ian Krop, MD, of Yale Cancer Center, is the corresponding author of The Lancet article.
Source: The ASCO Post
26 Apr 2023
News
Warning Signs of Oral Cancer
Do you know the warning signs of oral cancer? Some oral cancer symptoms are common and easily identifiable. Other symptoms are surprising, and you might miss them. Here, experts break down the symptoms of oral cancer you should be aware of, plus how to prevent oral cancer.
Source: HealthDay
25 Apr 2023
News
A new Yale research study will examine public health impacts of cancer-causing chemical in L.I. drinking water
Yale University scientists are preparing to launch a study on Long Island to determine the health effects of the chemical 1,4 dioxane, a contaminant likely to cause cancer in people, according to the U.S. Environmental Protection Agency. The Yale Superfund Research Center is looking for volunteers who live on Long Island, where the chemical is being detected in private wells and public water supply systems at higher levels than most of the rest of the country, to participate in the study.
Source: Riverhead Local
25 Apr 2023
News
Dr. Herbst on the Implications of the AEGEAN Trial in NSCLC
Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial (NCT03800134) in patients with resectable non–small cell lung cancer (NSCLC). At the 2023 AACR Annual Meeting, preliminary findings from the phase 3 trial were read out from the first interim analysis. The AEGEAN trial evaluated patients that received perioperative durvalumab (Imfinzi) plus neoadjuvant platinum-based chemotherapy compared with placebo with chemotherapy, Herbst begins, noting that the trial was positive. Investigators reported a hazard ratio of 0.68 and a 32% improvement in event-free survival (EFS). Moreover, the pathologic complete response rate was 17.2% compared with 4.3% in the control arm. However, the median follow-up was only 11.7 months, so the data are still early, Herbst expands.
Source: OncLive
24 Apr 2023
News
Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?
After excluding patients with targetable EGFR/ALK alterations, the team randomly allocated 740 patients who had good performance status (ECOG 0 or 1) to receive either neoadjuvant chemoimmunotherapy plus adjuvant immunotherapy or neoadjuvant chemotherapy alone.
Source: Medscape
20 Apr 2023